Abstract
In this review we examine the available information on the safety of antimalarials in pregnancy, from both animal and human studies. The antimalarials that can be used in pregnancy include (1) chloroquine, (2) amodiaquine, (3) quinine, (4) azithromycin, (5) sulfadoxine-pyrimethamine, (6) mefloquine, (7) dapsone-chlorproguanil, (8) artemisinin derivatives, (9) atovaquone-proguanil and (10) lumefantrine. Antimalarial drugs that should not be used in pregnancy including (1) halofantrine, (2) tetracycline/doxycycline, and (3) primaquine. There are few studies in humans on the pharmacokinetics, safety and efficacy of antimalarials in pregnancy. This is because pregnant women are systematically excluded from clinical trials. The absence of adequate safety data, especially in the first trimester, is an important obstacle to developing treatment strategies. The pharmacokinetics of most antimalarial drugs are also modified in pregnancy and dosages will need to be adapted. Other factors, including HIV status, drug interactions with antiretrovirals, the influence of haematinics and host genetic polymorphisms may influence safety and efficacy. For these reasons there is an urgent need to assess the safety and efficacy of antimalarial treatments in pregnancy, including artemisinin based combination therapies.
Keywords: Pregnancy, malaria, antimalarial drugs, human studies, animal studies
Current Drug Safety
Title: Antimalarial Drugs in Pregnancy: A Review
Volume: 1 Issue: 1
Author(s): Francois Nosten, Rose McGready, Umberto d'Alessandro, Ana Bonell, Francine Verhoeff, Clara Menendez, Thenonest Mutabingwa and Bernard Brabin
Affiliation:
Keywords: Pregnancy, malaria, antimalarial drugs, human studies, animal studies
Abstract: In this review we examine the available information on the safety of antimalarials in pregnancy, from both animal and human studies. The antimalarials that can be used in pregnancy include (1) chloroquine, (2) amodiaquine, (3) quinine, (4) azithromycin, (5) sulfadoxine-pyrimethamine, (6) mefloquine, (7) dapsone-chlorproguanil, (8) artemisinin derivatives, (9) atovaquone-proguanil and (10) lumefantrine. Antimalarial drugs that should not be used in pregnancy including (1) halofantrine, (2) tetracycline/doxycycline, and (3) primaquine. There are few studies in humans on the pharmacokinetics, safety and efficacy of antimalarials in pregnancy. This is because pregnant women are systematically excluded from clinical trials. The absence of adequate safety data, especially in the first trimester, is an important obstacle to developing treatment strategies. The pharmacokinetics of most antimalarial drugs are also modified in pregnancy and dosages will need to be adapted. Other factors, including HIV status, drug interactions with antiretrovirals, the influence of haematinics and host genetic polymorphisms may influence safety and efficacy. For these reasons there is an urgent need to assess the safety and efficacy of antimalarial treatments in pregnancy, including artemisinin based combination therapies.
Export Options
About this article
Cite this article as:
Nosten Francois, McGready Rose, d'Alessandro Umberto, Bonell Ana, Verhoeff Francine, Menendez Clara, Mutabingwa Thenonest and Brabin Bernard, Antimalarial Drugs in Pregnancy: A Review, Current Drug Safety 2006; 1 (1) . https://dx.doi.org/10.2174/157488606775252584
DOI https://dx.doi.org/10.2174/157488606775252584 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics Intracranial Non-traumatic Aneurysms in Children and Adolescents
Current Pediatric Reviews The Hemostasis System in Murine Atherosclerosis
Current Drug Targets Early Life Programming of Obesity: The Impact of the Perinatal Environment on the Development of Obesity and Metabolic Dysfunction in the Offspring.
Current Diabetes Reviews A Review of Maternal and Fetal Growth Factors in Diabetic Pregnancy
Current Diabetes Reviews Dendrimers as an Effective Nanocarrier in Cardiovascular Disease
Current Pharmaceutical Design Mitochondrial Encephalomyopathies in Children. Part I: Conventional MR Imaging Findings
Current Medical Imaging Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Extending Life Using Tissue and Organ Replacement
Current Aging Science Bone Disruption and Environmental Pollutants
Endocrine, Metabolic & Immune Disorders - Drug Targets A Pharmacological Review of Five Widely Used Traditional Medicinal Plants for Sedative-Hypnotic Effects in Bangladesh
Current Traditional Medicine Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy The Sensing of Membrane Microdomains Based on Pore-Forming Toxins
Current Medicinal Chemistry FTY720 (Fingolimod) Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment
Current Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Functions of S100 Proteins
Current Molecular Medicine Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Topics in Medicinal Chemistry